Evidence map›Paper›PMID 29720269›Full record

ArticleStem cell research & therapy2018

Acidic preconditioning of endothelial colony-forming cells (ECFC) promote vasculogenesis under proinflammatory and high glucose conditions in vitro and in vivo.

Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Mirta Schattner, Catherine Boisson-Vidal, Soledad Negrotto

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Photobiomodulation in 3D tissue engineering.Journal of biomedical optics · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. The change of intracellular zinc distribution after strong acid challenge.International journal of physiology, pathophysiology and pharmacology · 2021
    Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hebe Agustina MenaExperimental Thrombosis Laboratory, Institute of Experimental Medicine (IMEX), National Academy of Medicine-CONICET, Pacheco de Melo, 3081, Buenos Aires, Argentina.
Paula Romina ZubiryExperimental Thrombosis Laboratory, Institute of Experimental Medicine (IMEX), National Academy of Medicine-CONICET, Pacheco de Melo, 3081, Buenos Aires, Argentina.
Blandine DizierUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Mirta SchattnerExperimental Thrombosis Laboratory, Institute of Experimental Medicine (IMEX), National Academy of Medicine-CONICET, Pacheco de Melo, 3081, Buenos Aires, Argentina.
Catherine Boisson-VidalUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Soledad NegrottoExperimental Thrombosis Laboratory, Institute of Experimental Medicine (IMEX), National Academy of Medicine-CONICET, Pacheco de Melo, 3081, Buenos Aires, Argentina. solenegrotto@hematologia.anm.edu.ar.ORCID 0000-0002-4754-0085

Funding

Fondo para la Investigación Científica y Tecnológica PICT 2013-0612Fondo para la Investigación Científica y Tecnológica PICT 2015-1859
6 · The paper itself

Abstract

backgroundWe have previously demonstrated that acidic preconditioning of human endothelial colony-forming cells (ECFC) increased proliferation, migration, and tubulogenesis in vitro, and increased their regenerative potential in a murine model of hind limb ischemia without baseline disease. We now analyze whether this strategy is also effective under adverse conditions for vasculogenesis, such as the presence of ischemia-related toxic molecules or diabetes, one of the main target diseases for cell therapy due to their well-known healing impairments.

methodsCord blood-derived CD34

resultsWe found that acidic preconditioning increased ECFC adhesion and the release of pro-angiogenic molecules, and protected ECFC from the cytotoxic effects of monosodium urate crystals, histones, and tumor necrosis factor (TNF)α, which induced necrosis, pyroptosis, and apoptosis, respectively. Noncytotoxic concentrations of high glucose, TNFα, or their combination reduced ECFC proliferation, stromal cell-derived factor (SDF)1-driven migration, and tubule formation on a basement membrane matrix, whereas almost no inhibition was observed in preconditioned ECFC. In type 2 diabetic mice, intravenous administration of preconditioned ECFC significantly induced blood flow recovery at the ischemic limb as measured by Doppler, compared with the phosphate-buffered saline (PBS) and nonpreconditioned ECFC groups. Moreover, the histologic analysis of gastrocnemius muscles showed an increased vascular density and reduced signs of inflammation in the animals receiving preconditioned ECFC.

conclusionsAcidic preconditioning improved ECFC survival and angiogenic activity in the presence of proinflammatory and damage signals present in the ischemic milieu, even under high glucose conditions, and increased their therapeutic potential for postischemia tissue regeneration in a murine model of type 2 diabetes. Collectively, our data suggest that acidic preconditioning of ECFC is a simple and inexpensive strategy to improve the effectiveness of cell transplantation in diabetes, where tissue repair is highly compromised.

Indexed as

AcidsAnimalsCell DifferentiationCell ProliferationDiabetes Mellitus, ExperimentalDisease Models, AnimalEndothelial Progenitor CellsGlucoseHumansMaleMiceMice, NudeNeovascularization, PhysiologicAcidsGlucoseAcidic preconditioningAngiogenesisHind limb ischemiaHuman endothelial colony forming cellsInflammationType 2 diabetesVasculogenesis

Identifiers

PMID29720269
PMCPMC5930427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.